Avalo Therapeutics, Inc.
NASDAQ:AVTXBiotechnology
-$0.34 today
- Market cap
- $387.41M
- Beta
- 0.82
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$4.21
Volume 1.58M
Average 1.61M
AVTX Account Payables
Amounts the company owes suppliers for goods and services received.
Avalo Therapeutics, Inc.NASDAQ: AVTX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 47.7% from a year ago
Account payables stood at $356K at the end of Q1 FY2026, down 47.7% from a year earlier and up 159.9% from the prior quarter. Over 3 fiscal years it compounded at -63.8% a year.
Context
- Account payables amounted to 0.4% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
- Account payables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -47.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 137K USD
- Year-over-year change
- -51.6%
- 4-year CAGR
- -55.1%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 137K | -51.6% |
| FY2024 | 2024-12-31 | 283K | -36.5% |
| FY2023 | 2023-12-31 | 446K | -84.5% |
| FY2022 | 2022-12-31 | 2.88M | -14.5% |
| FY2021 | 2021-12-31 | 3.37M | — |
Account Payables vs competitors
How AVTX compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -47.7% is the 7th highest of 9, against a peer median of +24.9%.
- Account payables amounts to 0.4% of total assets for AVTX, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $14.73M USD | +131.8% | +8.3% | 7.4% | |
| Jun 2026 | $12.65M USD | -31.8% | +2.4% | 1.7% | |
| Mar 2026 | $10.51M USD | +90.9% | +33.3% | 5.5% | |
| Sep 2026 | $9.47M USD | +26.9% | +136.0% | 0.9% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €7.58M EUR | — | — | 4.6% |
| Mar 2026 | $7.52M USD | +22.8% | +11.6% | 2.3% | |
| Mar 2026 | $6.59M USD | +127.0% | +18.1% | 4.5% | |
| Mar 2026 | $653K USD | -75.9% | -15.1% | 1.0% | |
| Mar 2026 | €367.06K EUR | -95.6% | +2.7% | 0.8% | |
| Mar 2026 | $356K USD | -47.7% | -63.8% | 0.4% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AVTX) | — | +24.9% | +10.0% | 2.3% | |
Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54.59M | 13.17M | 7.42M | 134.55M | 15.86M |
| Short-term Investments | 0 | 0 | 0 | 0 | 82.48M |
| Net Receivables | 4.8M | 1.92M | 136K | 611K | 0 |
| Inventory | 38K | 20K | 0 | 0 | 0 |
| Other Current Assets | 51K | 1.31M | 844K | 3.73M | 6.95M |
| Total Current Assets | 61.85M | 16.42M | 8.4M | 138.89M | 105.29M |
| Property, Plant & Equipment (Net) | 2.7M | 2.41M | 1.97M | 1.21M | 460K |
| Goodwill | 14.41M | 14.41M | 10.5M | 10.5M | 10.5M |
| Intangible Assets | 38K | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.23M | 131K | 131K | 131K | 210K |
| Total Non-current Assets | 18.37M | 16.95M | 12.6M | 11.84M | 11.17M |
| Total Assets | 80.21M | 33.37M | 20.99M | 150.73M | 116.46M |
| Account Payables | 3.37M | 2.88M | 446K | 283K | 137K |
| Short-term Debt | 0 | 5.93M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 88K | 0 | 0 | 0 |
| Other Current Liabilities | 4.32M | 3.18M | 3.06M | 3.24M | 12.41M |
| Total Current Liabilities | 19.89M | 22.11M | 4.62M | 6.96M | 12.94M |
| Long-term Debt | 32.83M | 13.49M | 0 | 0 | 2M |
| Deferred Tax Liabilities | 113K | 141K | 155K | 270K | 434K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.3M | 8.54M | 8.92M | 10.47M | 18M |
| Total Non-current Liabilities | 37.24M | 22.17M | 9.07M | 10.74M | 20.47M |
| Total Liabilities | 57.13M | 44.28M | 13.69M | 17.7M | 33.41M |
| Common Stock | 9K | 0 | 1K | 10K | 18K |
| Retained Earnings | (262.17M) | (303.82M) | (335.13M) | (370.26M) | (448.52M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 68K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 23.08M | (10.92M) | 7.3M | 133.03M | 83.05M |
| Total Debt | 33.32M | 19.95M | 537K | 568K | 2.43M |
| Net Debt | (21.27M) | 6.78M | (6.88M) | (133.98M) | (13.43M) |
Avalo Therapeutics, Inc.
NASDAQ:AVTX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.